Want to see INBP full AI Analyst Report?
Top Page
Integrated BioPharma
(OTC:INBP)
Select Model
Select Model
Rating:49Neutral
Price Target:
$0.16
▼(-53.24% Downside)
Action:Reiterated
Date:07/02/26
The score is held back primarily by deteriorating TTM fundamentals (sharp revenue decline and negative margins) and bearish technicals (price below key moving averages with negative MACD and low RSI). Balance-sheet flexibility and positive free cash flow provide partial support, and the extended credit facilities modestly improve liquidity visibility, but valuation is constrained by negative earnings and no dividend yield data.
Positive Factors
Integrated contract manufacturing and distribution
A dual business model (contract manufacturing plus product distribution) provides diversified, fee-based revenue streams and multiple customer touchpoints. That structural mix supports recurring manufacturing revenue while distribution margins offer complementary cash generation across economic cycles.
Negative Factors
Material revenue decline and negative margins
A sharp, multi-quarter revenue decline combined with a negative net margin signals structural demand or pricing pressure. Shrinking gross margins (from ~14.9% in 2021 to ~5.9% TTM) suggest lasting margin compression that undermines sustainable profitability and return on capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated contract manufacturing and distribution
A dual business model (contract manufacturing plus product distribution) provides diversified, fee-based revenue streams and multiple customer touchpoints. That structural mix supports recurring manufacturing revenue while distribution margins offer complementary cash generation across economic cycles.
Read all positive factors
Integrated BioPharma (INBP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.12M
Dividend YieldN/A
Average Volume (3M)15.15K
Price to Earnings (P/E)―
Beta (1Y)0.01
Revenue Growth-8.83%
EPS Growth-228.43%
CountryUS
Employees153
SectorConsumer Defensive
Sector Strength42
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-0.06
Shares Outstanding31,059,610
10 Day Avg. Volume31,065
30 Day Avg. Volume15,153
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.53
Price to Sales (P/S)0.20
P/FCF Ratio5.77
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue0.07
Enterprise Value/Gross Profit1.53
Enterprise Value/Ebitda61.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Integrated BioPharma Business Overview & Revenue Model
Company Description
Integrated BioPharma, Inc., together with its subsidiaries, engages in the manufacturing, distributing, marketing and sale of vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. The company operate...
How the Company Makes Money
Integrated BioPharma primarily makes money in two ways: (1) contract manufacturing revenue and (2) distribution/wholesale revenue. On the manufacturing side, the company earns fees by producing dietary/nutritional supplement products for third-par...
Integrated BioPharma Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
70
Positive
Cash Flow
66
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 48.25M | 54.35M | 50.32M | 50.67M | 56.25M | 63.56M |
| Gross Profit | 2.24M | 5.56M | 3.88M | 4.06M | 6.55M | 9.48M |
| EBITDA | 56.00K | 3.38M | 1.47M | 1.27M | 3.56M | 6.61M |
| Net Income | -1.65M | 808.00K | 112.00K | -34.00K | 3.84M | 8.01M |
Balance Sheet | ||||||
| Total Assets | 26.67M | 24.90M | 26.21M | 25.43M | 25.25M | 25.44M |
| Cash, Cash Equivalents and Short-Term Investments | 5.83M | 3.62M | 1.68M | 1.32M | 331.00K | 210.00K |
| Total Debt | 3.35M | 1.01M | 1.80M | 2.67M | 2.06M | 4.33M |
| Total Liabilities | 7.69M | 4.58M | 6.97M | 6.57M | 6.67M | 11.11M |
| Stockholders Equity | 18.98M | 20.32M | 19.24M | 18.86M | 18.57M | 14.33M |
Cash Flow | ||||||
| Free Cash Flow | 2.83M | 1.87M | 390.00K | 1.12M | 3.60M | 2.75M |
| Operating Cash Flow | 3.03M | 2.06M | 943.00K | 1.23M | 4.09M | 3.05M |
| Investing Cash Flow | -195.00K | -205.00K | -553.00K | -111.00K | -465.00K | -199.00K |
| Financing Cash Flow | 34.00K | 78.00K | -29.00K | -136.00K | -3.50M | -3.04M |
Integrated BioPharma Technical Analysis
Negative
0.34
Price Trends
0.19
Negative
0.23
Negative
0.27
Negative
Market Momentum
>-0.01
Negative
31.80
Neutral
56.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBP, the sentiment is Negative. The current price of 0.34 is above the 20-day moving average (MA) of 0.17, above the 50-day MA of 0.19, and above the 200-day MA of 0.27, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 31.80 is Neutral, neither overbought nor oversold. The STOCH value of 56.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INBP.
Integrated BioPharma Risk Analysis
Integrated BioPharma disclosed 20 risk factors in its most recent earnings report. Integrated BioPharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Integrated BioPharma Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $104.80M | 17.28 | 14.03% | ― | 42.27% | -33.19% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
49 Neutral | $5.12M | -3.01 | -1.02% | ― | -8.83% | -228.43% | |
46 Neutral | $5.17M | -0.56 | -116.36% | ― | ― | ― | |
45 Neutral | $9.56M | -5.04 | -3.59% | ― | -21.70% | -109.55% | |
44 Neutral | $14.18M | -0.94 | -17.43% | ― | 12.37% | -69.61% | |
43 Neutral | $72.43M | -0.07 | -371.70% | ― | -81.88% | -672.07% |
* Consumer Defensive Sector Average
INBP
Integrated BioPharma
0.16
-0.15
-48.39%
NAII
Natural Alternatives International
2.22
-1.27
-36.39%
SOWG
Sow Good
3.47
-8.62
-71.31%
FTLF
FitLife Brands
11.06
-1.68
-13.19%
BON
Bon Natural Life
1.16
-0.25
-17.73%
HCWC
Healthy Choice Wellness Corp. Class A
0.19
-0.24
-55.58%
Integrated BioPharma Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Integrated BioPharma Updates and Extends Credit Facilities
Positive
Jul 2, 2026
On June 30, 2026, Integrated BioPharma and Manhattan Drug Company amended their loan arrangements with PNC Bank, extending the expiration of their existing committed revolving line of credit to April 14, 2027 while maintaining the $4,000,000 borro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.